Table 3.
IC50 values of fevipiprant-inhibited eosinophil shape change, ILC2 migration and IL-5 and IL-13 cytokine secretion of ILC2s
| IC50 fevipiprant [nM] | ||||
|---|---|---|---|---|
| Metabolite | shape change (n = 3–5) | Migration (n = 4) | IL-5 (n = 4) | IL-13 (n = 4) |
| PGD2 | 0.9 ± 0.2 | 2.4 ± 0.6 | 4.2 ± 0.8 | 5.1 ± 1.1 |
| DK-PGD2 | 0.1 ± 0.0 | 1.9 ± 0.7 | 6.5 ± 1.6 | 8.5 ± 2.1 |
| ∆12-PGD2 | 0.1 ± 0.0 | 4.9 ± 1.3 | 4.8 ± 1.2 | 4.8 ± 1.3 |
| 15-deoxy-∆12,14-PGD2 | 0.5 ± 0.3 | 4.6 ± 2.0 | 4.5 ± 1.7 | 4.6 ± 1.4 |
| 9α,11β-PGF2 | 0.9 ± 0.1 | 10.9 ± 7.8 | –a | –a |
| PGJ2 | 0.5 ± 0.2 | 3.7 ± 0.6 | 4.0 ± 1.0 | 5.9 ± 3.6 |
| ∆12-PGJ2 | 0.6 ± 0.3 | 3.1 ± 0.5 | 3.7 ± 0.9 | 4.6 ± 1.6 |
| 15-deoxy-∆12,14-PGJ2 | –a | 3.8 ± 0.8 | 2.3 ± 0.9 | 2.6 ± 0.9 |
Values were calculated from 3 to 5 experiments and are given as mean ± standard error of the mean (SEM)
aCurve fit was ambiguous, IC50 values could not be determined